 uniQure has submitted data to the FDA that suggest that etranacogene dezaparvovec AMT-061 is highly unlikely to be the cause of liver cancer in a patient in the pivotal trial. FTC review of the transaction with CSL Behring is ongoing and is projected to close during the second quarter of 2021. 